Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus reuteri CCFM1040
- Development stage
- Preclinical
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus reuteri CCFM1040 is a specific strain of probiotic bacteria isolated from unpasteurized milk. It is under investigation for its potential therapeutic effects on respiratory allergic diseases, such as allergic rhinitis and asthma. Clinical studies suggest that L. reuteri CCFM1040 may alleviate symptoms and improve quality of life in patients by modulating the gut microbiota and the host's immune system. Its mechanism is believed to involve the reduction of type 2 inflammation, partly by increasing the population of regulatory T cells (Treg cells), thereby supporting the "one airway, one disease" concept for treating concurrent allergic rhinitis and asthma.
- Brand names
- ProBioFlora Reuteri
- Other names
- lactobacillus CCFM1040乳杆菌CCFM1040
Beyond the preview
Go deeper on Lactobacillus reuteri CCFM1040.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus reuteri CCFM1040.